Search

Your search keyword '"Mego, David"' showing total 24 results
Start Over Author "Mego, David" Language english
24 results on '"Mego, David"'

1. Assessment of Vascular Patency and Inflammation with Intravascular Optical Coherence Tomography in Patients with Superficial Femoral Artery Disease Treated with Zilver PTX Stents

Author

Hoyt, Taylor, Feldman, Marc D., Okutucu, Sercan, Lendel, Vasili, Marmagkiolis, Konstantinos, McIntosh, Victoria, Ates, Ismail, Kose, Gulcan, Mego, David, Paixao, Andre, Iliescu, Cezar, Park, Jongwan, Shaar, Mohammad, Avci, Recep, McElroy, Austin, Dijkstra, Jouke, Milner, Thomas E., and Cilingiroglu, Mehmet

Published
2020
Full Text
View/download PDF

2. Balloon-Expandable Vascular Covered Stent in the Treatment of Iliac Artery Occlusive Disease: 9-Month Results from the BOLSTER Multicenter Study

Author

Elmasri, Fakhir, Robinson, William, Beasley, Robert, Mego, David, Marica, Silviu, Bersin, Robert, Kujath, Scott, Razavi, Mahmood, Teßarek, Jörg, Schulte, Karl-Ludwig, Laird, John R., Zeller, Thomas, Holden, Andrew, Scheinert, Dierk, Moore, Erin, Mendes, Robert, Schmiedel, Rainer, Settlage, Richard, Lansky, Alexandra, and Jaff, Michael R.

Published
2019
Full Text
View/download PDF

18. MitraClip Deployed via Left Femoral Vein in an 85-Year-Old Woman with Mitral Regurgitation.

Author

Edupuganti, Mohan Mallikarjuna Rao, Mutlu, Deniz, Mego, David M., Marmagkiolis, Kostas, and Cilingiroglu, Mehmet

Subjects
*FEMORAL vein, *MITRAL valve surgery, *MITRAL valve insufficiency, *HEART valve prosthesis implantation, *HEART valve diseases
Abstract

The MitraClip system can be used to control regurgitant blood flow in patients with mitral regurgitation who cannot tolerate open surgery to replace the mitral valve. Technical limitations make the right femoral vein the standard access point for placing the MitraClip. However, this route is not always suitable. We present the case of an 85-year-old woman in whom we successfully used a left-sided approach for inserting a MitraClip because her right femoral vein was occluded. This apparently novel left femoral approach merits consideration as an option for device insertion when right femoral vein access is precluded. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

24. A poly-N-acetyl glucosamine hemostatic dressing for femoral artery access site hemostasis after percutaneous coronary intervention: a pilot study.

Author

Mego D, Thomas M, Stewart J, Rollefson W, Flaherty P, Murphy B, and Ribeiro P

Subjects
Acetylglucosamine administration & dosage, Acetylglucosamine adverse effects, Administration, Topical, Aged, Anticoagulants therapeutic use, Female, Hemostatics administration & dosage, Hemostatics adverse effects, Hirudins, Humans, Male, Peptide Fragments therapeutic use, Pilot Projects, Recombinant Proteins therapeutic use, Retrospective Studies, Thrombosis prevention & control, Time Factors, Walking, Acetylglucosamine therapeutic use, Angioplasty, Balloon, Coronary methods, Biological Dressings, Femoral Artery physiology, Hemostasis physiology, Hemostatics therapeutic use, Regional Blood Flow physiology
Abstract

Background: Arterial puncture closure devices have improved time to hemostasis and ambulation after percutaneous coronary intervention (PCI) relative to traditional manual compression, though complication rates for both methods leave room for improvement. In a pilot registry, the authors evaluated a topical hemostatic dressing containing poly-N-acetyl glucosamine (p-GlcNAc) post PCI in fully anticoagulated patients., Methods and Results: In 100 patients undergoing PCI via the common femoral artery in the short-stay unit, the p-GlcNAc hemostatic dressing was applied with 15 minutes of manual compression at arterial access sites after arterial sheath removal. Procedural antiplatelet and anticoagulation therapies were aspirin, clopidogrel and bivalirudin. Patients were observed during 2 hours of bed rest and attempted to ambulate 2 hours post hemostasis. Effectiveness was assessed based on times to hemostasis and ambulation. Data were stratified by time elapsed since bivalirudin bolus or discontinuation of infusion (30 minutes, > 30-60 minutes, > 60 minutes). Mean time to hemostasis was 15.5 minutes. Mean time from hemostasis to ambulation was 2.08 hours; 87% of patients ambulated at 2 hours. Sheaths were removed at a mean 40.38 minutes after discontinuing bivalirudin. Anticoagulation status (as assessed by time since discontinuation of bivalirudin) did not influence time to hemostasis or ambulation. There was a single major complication (pseudoaneurysm), two minor rebleeds requiring additional manual compression, and 1 hematoma > 5 cm., Conclusions: This p-GlcNAc topical hemostatic dressing safely achieved hemostasis at arterial access sites and early ambulation, even with nearly immediate sheath removal after PCI with systemic anticoagulation using bivalirudin.

Published
2010

Catalog

Books, media, physical & digital resources
See catalog results